Review Times Remain A GDUFA II Topic
Executive Summary
Talks continue to include ANDA review times and metrics, increasing potential for more changes.
You may also be interested in...
ANDA Submission Wave Continues; Is A Crest Near?
Sponsors continue to submit generic drug applications at elevated rate for second-straight month as approvals increase.
ANDA Submission Wave Continues; Is A Crest Near?
Sponsors continue to submit generic drug applications at elevated rate for second-straight month as approvals increase.
GDUFA II: Inspection Information Takes Center Stage
Sponsors say transparency is important as generic drug user fee negotiations move to inspection policy.